A Prospective, Multi-center, Randomized, Parallel-group, Controlled Study to Evaluate the Efficacy and Safety of OTX-TIC (Travoprost) Intracameral Implant in Subjects With Open-angle Glaucoma (OAG) or Ocular Hypertension (OHT)
Latest Information Update: 12 Apr 2024
At a glance
- Drugs Travoprost (Primary) ; Bimatoprost
- Indications Ocular hypertension; Open-angle glaucoma
- Focus Therapeutic Use
- Sponsors Ocular Therapeutix
- 06 Apr 2024 According to Ocular Therapeutics media release, positive data from PAXTRAVA 26 ug treatment arm presented at 2024 American Society of Cataract and Refractive Surgery (ASCRS) Annual Meeting.
- 06 Apr 2024 According to Ocular Therapeutics media release, due to elevations in IOP observed in seven out of the 16 subjects enrolled in the PAXTRAVA 5 µg arm of the trial, the company closed enrollment in this arm and continued with the PAXTRAVA 26 ug and DURYSTA arms of the trial.
- 06 Apr 2024 Primary endpoint (Efficacy Outcome: IOP changes from Baseline(26 ug dose)) has been met.